65 / 69
65
BCR-ABL mutations in patients with chronic myeloid
leukemia treated with imatinib mesylate. Leukemia
2006;20:1767-73.
77.
Khorashad JS, de Lavallade H, Apperley JF, Milojkovic D,
Reid AG, Bua M, et al. Finding of kinase domain
mutations in patients with chronic phase chronic myeloid
leukemia responding to imatinib may identify those at
high risk of disease progression. J Clin Oncol 2008;26:4806-
13.
78.
Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C,
Koller C, et al. Long-term outcome of patients with chronic
myeloid leukemia treated with second-generation tyrosine
kinase inhibitors after imatinib failure is predicted by the
in vitro sensitivity of BCR-ABL kinase domain mutations.
Blood 2009;114:2037-43.
79.
Ono T, Miyawaki S, Kimura F, Kanamori H, Ohtake S,
Kitamura K, et al. BCR-ABL1 mutations in patients with
imatinib-resistant
Philadelphia
chromosome-positive
leukemia by use of the PCR-Invader assay. Leuk Res
2011;35:598-603.
80.
Meggyesi N, Kozma A, Halm G, Nahajevszky S, Bátai A,
Fekete S, et al. Additional chromosome abnormalities,
BCR-ABL tyrosine kinase domain mutations and clinical
outcome in Hungarian tyrosine kinase inhibitor-resistant
chronic myelogenous leukemia patients. Acta Haematol
2012;127:34-42.
81.
Müller MC, Cortes JE, Kim DW, Druker BJ, Erben P,
Pasquini R, et al. Dasatinib treatment of chronic-phase
chronic myeloid leukemia: analysis of responses according
to preexisting BCR-ABL mutations. Blood 2009;114:4944-
53.
82.
O’Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase
domain mutations, drug resistance, and the road to a cure
for chronic myeloid leukemia. Blood 2007;110:2242-9.